News

Kwality Pharmaceuticals Limited announced that its members approved the regularization of Swanith Kapoor as a Non-Executive Independent Director for a term of five consecutive years, effective June 2, 2026, to June 1, 2031, and the reappointment of Aditya Arora as Whole Time Director for a period of five years, effective September 30, 2026, to September 29, 2031.

Kwality Pharmaceuticals announced that the 43th Annual General Meeting(AGM) of the company will be held on 31 August 2026.

Net profit of Kwality Pharmaceuticals rose 114.75% to Rs 25.62 crore in the quarter ended June 2026 as against Rs 11.93 crore during the previous quarter ended June 2025. Sales rose 45.63% to Rs 162.35 crore in the quarter ended June 2026 as against Rs 111.48 crore during the previous quarter ended June 2025. ParticularsQuarter EndedJun. 2026Jun. 2025% Var. Sales162.35111.48 46 OPM %25.2721.68 - PBDT38.9821.79 79 PBT33.9917.03 100 NP25.6211.93 115 Powered by Capital Market - Live News

Kwality Pharmaceuticals will hold a meeting of the Board of Directors of the Company on 10 August 2026.

Kwality Pharmaceuticals has achieved a significant milestone in its biologics development journey after receiving permission from the Central Drugs Standard Control Organization (CDSCO) to manufacture pilot batches of Pembroluzimab for preclinical studies.The approval follows a comprehensive review of the product`s development data submitted by the Company`s R&D team. Based on the data evaluated, CDSCO has granted permission to proceed with pilot-scale manufacturing for the generation of preclinical batches, marking the product`s transition from the research and development stage to Pre-Clinical stage.